Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity

被引：0

作者：

Le, X. ^{[1
]}

Robichaux, J. P. ^{[2
]}

Nilsson, M. B. ^{[3
]}

Ramaswamy, V. ^{[4
]}

Ravichandran, A. ^{[5
]}

Wu, J. ^{[6
]}

Elamin, Y. Y.

Hong, L. ^{[7
]}

Udagawa, H. ^{[8
]}

Socinski, M. ^{[9
]}

Bhat, G. ^{[10
]}

Lebel, F. ^{[11
]}

Vincent, S. ^{[12
]}

Bunn, V. ^{[13
]}

Su, Z. ^{[13
]}

Lawson, J. ^{[14
]}

Cross, J. ^{[4
]}

Heymach, J. ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA

[3] MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA

[4] MD Anderson Canc Ctr, Computat Chem, Houston, TX USA

[5] NASA Ames Res Ctr, KBR, Moffett Field, CA USA

[6] MD Anderson Canc Ctr, Radiol, Houston, TX USA

[7] MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol Dept, Houston, TX USA

[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[9] Florida Hosp Canc Inst, Oncol, Orlando, FL USA

[10] Spectrum Pharmaceut, Dept Clin Sci, Irvine, MA USA

[11] Spectrum Pharmaceut, Res & Dev, Irvine, MA USA

[12] Takeda Millennium Oncol USA, Oncol, Cambridge, MA USA

[13] Takeda Dev Ctr Amer Inc, Oncol, Cambridge, MA USA

[14] NASA Ames Res Ctr, Biol, Moffett Field, CA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2410

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1377P

引用

页数：1

共 50 条

[1] Sensitivity of EGFR exon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR
Yasuda, Hiroyuki
Sng, Natasha J.
Yeo, Wee-Lee
Figueiredo-Pontes, Lorena L.
Kobayashi, Susumu
Costa, Daniel B.
[J]. CANCER RESEARCH, 2012, 72
[2] SENSITIVITY OF EGFR EXON 20 INSERTION MUTATIONS TO EGFR INHIBITORS IS DETERMINED BY THEIR LOCATION WITHIN THE TYROSINE KINASE DOMAIN OF EGFR
Yasuda, Hiroyuki
Figueiredo-Pontes, Lorena L. D.
Tenen, Daniel G.
Kobayashi, Susumu
Costa, Daniel B.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S107 - S107
[3] Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR.
Costa, Daniel Botelho
Yasuda, Hiroyuki
Sng, Natasha J.
Yeo, Wee-Lee
de Figueiredo-Pontes, Lorena Lobo
Tenen, Daniel G.
Kobayashi, Susumu
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[4] Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer
Park, Siyeon
Park, Seongyeol
Kim, Tae Min
Kim, Soyeon
Koh, Jaemoon
Lim, Joonoh
Yi, Kijong
Yi, Boram
Ju, Young Seok
Kim, Miso
Keam, Bhumsuk
Kim, Jung Sun
Jeon, Yoon Kyung
Kim, Dong-Wan
Kim, Young Tae
Heo, Dae Seog
[J]. EUROPEAN JOURNAL OF CANCER, 2024, 208
[5] Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Elamin, Yasir Y.
Robichaux, Jacqulyne P.
Carter, Brett W.
Altan, Mehmet
Tran, Hai
Gibbons, Don L.
Heeke, Simon
Fossella, Frank, V
Lam, Vincent K.
Le, Xiuning
Negrao, Marcelo, V
Nilsson, Monique B.
Patel, Anisha
Vijayan, R. S. K.
Cross, Jason B.
Zhang, Jianjun
Byers, Lauren A.
Lu, Charles
Cascone, Tina
Feng, Lei
Luthra, Rajyalakshmi
San Lucas, Francis A.
Mantha, Geeta
Routbort, Mark
Blumenschein, George, Jr.
Tsao, Anne S.
Heymach, John, V
[J]. CANCER CELL, 2022, 40 (07) : 754 - +
[6] Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR
Floc'h, Nicolas
Ashton, Susan
Bianco, Ambra
Colclough, Nicola
Cross, Darren A. E.
Cuomo, Maria Emanuela
Finlay, M. Raymond V.
Martin, Matthew J.
Menard, Ludovic
McKerrecher, Darren
O'Neill, Daniel J.
Orme, Jonathan P.
Staniszewska, Anna D.
Ward, Richard A.
Yates, James W. T.
[J]. CANCER RESEARCH, 2017, 77
[7] EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
Chelabi, Samy
Mignard, Xavier
Leroy, Karen
Monnet, Isabelle
Brosseau, Solenn
Theou-Anton, Nathalie
Massiani, Marie-Ange
Friard, Sylvie
Duchemann, Boris
Fabre, Elizabeth
Giroux-Leprieur, Etienne
Cadranel, Jacques
Wislez, Marie
[J]. CANCERS, 2021, 13 (20)
[8] FDA approves first EGFR exon 20 targeted kinase inhibitor
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2021, 20 : 806 - 806
[9] FDA approves first EGFR exon 20 targeted kinase inhibitor
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (11) : 806 - 806
[10] Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
Floc'h, Nicolas
Martin, Matthew J.
Riess, Jonathan W.
Orme, Jonathan P.
Staniszewska, Anna D.
Menard, Ludovic
Cuomo, Maria Emanuela
O'Neill, Daniel J.
Ward, Richard A.
Finlay, M. Raymond V.
McKerrecher, Darren
Cheng, Mingshan
Vang, Daniel P.
Burich, Rebekah A.
Keck, James G.
Gandara, David R.
Mack, Philip C.
Cross, Darren A. E.
[J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 885 - 896

← 1 2 3 4 5 →